NeoNeuro SAS and the Australian Imaging, Biomarker & Lifestyle Flagship Study of Ageing (AIBL) group are pleased to announce that they have entered into a collaboration to validate the performance of the Aptamarker platform for Alzheimer’s disease diagnosis.
The Aptamarker platform is a global first in terms of enabling the characterization of millions of biomarkers simultaneously against a pathology in blood serum. Success with this project has the potential to provide new insights into subtypes of the disease by providing personalized characterization of individuals over time.
NeoNeuro is a French subsidiary of the Canadian aptamer company, NeoVentures Biotechnology Inc. The Aptamarker platform was developed by NeoNeuro with collaboration from the Institut du cerveau et de la moelle épinière (Institut du Cerveau – ICM) within the IPEPS incubator in Paris with financial support from the Banque Publique d’Investissement (BPI).